EF Hutton Maintains Buy on FibroBiologics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for FibroBiologics (NASDAQ:FBLG) and maintained a price target of $16.
September 13, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for FibroBiologics and maintained a price target of $16, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $16 price target by EF Hutton suggests positive sentiment and confidence in FibroBiologics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100